Clinical trial
A Randomized, Blinded, Parallel Controlled Phase 3 Clinical Study to Evaluate the Safety and Immunogenicity of the Diphtheria, Tetanus and Three-components Acellular Pertussis Combined Vaccine, Adsorbed in Healthy Infants at the Age of 2 Months and 3 Months
NCT05091619 is registered in ClinicalTrials.gov with China National Biotec Group Company Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Blinded, Parallel Controlled Phase 3 Clinical Study to Evaluate the Safety and Immunogenicity of the Diphtheria, Tetanus and Three-components Acellular Pertussis Combined Vaccine, Adsorbed in Healthy Infants at the Age of 2 Months and 3 Months
- Lead sponsor
- China National Biotec Group Company Limited
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- October 22, 2021
- Completion date
- September 22, 2027
- Enrollment
- 2,898 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.